Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 4/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 15/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20647035 | 0.90 | MCHR1 (0.37) | MCHR1ROCK2 | |
| SCHEMBL24247859 | 0.89 | CACNA1H (0.42) | ROCK2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL20646801 | 0.78 | ROCK2 (0.35) | ROCK2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL17454506 | 0.76 | ROCK2 (0.48) | ROCK2ALDH1A1 | |
| SCHEMBL20647157 | 0.75 | ROCK2 (0.40) | MCHR1ROCK2 | |
| SCHEMBL17453654 | 0.75 | HRH3 (0.42) | ROCK2KDM4EALDH1A1 | |
| SCHEMBL17454418 | 0.75 | ROCK2 (0.41) | ROCK2 | |
| SCHEMBL17324758 | 0.74 | ROCK2 (0.40) | ROCK2KDM4EALDH1A1 | |
| SCHEMBL17454381 | 0.74 | ROCK2 (0.51) | ROCK2ALDH1A1 | |
| SCHEMBL17454461 | 0.74 | HRH3 (0.39) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3954681-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2022-02-16 | — | — | EP | disclosed |
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190016735-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016735-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | ROCK1, MYLK, RHOA | MCHR1 3337/4885ROCK2 5/4885KDM4E 2298/4885 |
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | ROCK1, MYLK, RHOA | MCHR1 3337/4885ROCK2 5/4885KDM4E 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.